Allianz Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Allianz Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,015	Closed	-$306K	–	2702
2021 Q4	$306K	Sell	6,015 -31	-0.5%	-$1.61K	﹤0.01%	2370
2021 Q3	$337K	Buy	6,046 +360	+6%	+$17.7K	﹤0.01%	2374
2021 Q2	$243K	Hold	5,686	–	–	﹤0.01%	2312
2021 Q1	$237K	Sell	5,686 -720	-11%	-$33.4K	﹤0.01%	2090
2020 Q4	$298K	Sell	6,406 -413	-6%	-$19.3K	﹤0.01%	1747
2020 Q3	$290K	Sell	6,819 -416	-6%	-$18.2K	﹤0.01%	1726
2020 Q2	$347K	Buy	+7,235	New	+$361K	﹤0.01%	2160
2018 Q3	–	Sell	-28,300	Closed	-$2.14M	–	2753
2018 Q2	$2.14M	Sell	28,300 -105,722	-79%	-$6.65M	﹤0.01%	1915
2018 Q1	$7.06M	Buy	134,022 +410	+0.3%	+$23.8K	0.01%	1396
2017 Q4	$7.14M	Buy	133,612 +7,360	+6%	+$410K	0.01%	1482
2017 Q3	$7.53M	Sell	126,252 -21,924	-15%	-$1.33M	0.01%	1431
2017 Q2	$11.7M	Sell	148,176 -16,083	-10%	-$1.32M	0.01%	1250
2017 Q1	$13.6M	Buy	164,259 +62,223	+61%	+$4.63M	0.01%	1197
2016 Q4	$8.1M	Sell	102,036 -6,472	-6%	-$470K	0.01%	1451
2016 Q3	$7.59M	Sell	108,508 -32,777	-23%	-$1.82M	0.01%	1447
2016 Q2	$5.48M	Sell	141,285 -125,062	-47%	-$5.21M	0.01%	1469
2016 Q1	$10.8M	Sell	266,347 -28,424	-10%	-$1.8M	0.01%	1089
2015 Q4	$26.1M	Sell	294,771 -61,784	-17%	-$4.88M	0.03%	627
2015 Q3	$26.4M	Buy	356,555 +28,099	+9%	+$2.34M	0.03%	605
2015 Q2	$26.6M	Buy	328,456 +35,579	+12%	+$2.32M	0.03%	664
2015 Q1	$12.3M	Buy	292,877 +148,253	+103%	+$4.21M	0.01%	868
2014 Q4	$2.24M	Sell	144,624 -1,475	-1%	-$18.8K	﹤0.01%	1503
2014 Q3	$1.85M	Buy	146,099 +23,055	+19%	+$286K	﹤0.01%	1462
2014 Q2	$1.76M	Sell	123,044 -2,896	-2%	-$33K	﹤0.01%	1249
2014 Q1	$1.61M	Buy	+125,940	New	+$1.71M	﹤0.01%	1279

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Allianz Asset Management's EGRX Position: Q1 2022 in Review

Allianz Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 6,015 shares — an estimated $306K sold.

Allianz Asset Management first reported a position in EGRX in Q1 2014 and held it in 25 quarters. The position peaked at $26.6M in Q2 2015. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

Allianz Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Allianz Asset Management sold 6,015 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $306K.
Allianz Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 25 quarters.
Allianz Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $26.6M in Q2 2015.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Allianz Asset Management's 13F filing for Q1 2022, filed 13 May 2022.